NNVC Stock Overview
A clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
NanoViricides, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.40 |
| 52 Week High | US$3.59 |
| 52 Week Low | US$1.00 |
| Beta | 0.97 |
| 11 Month Change | -6.35% |
| 3 Month Change | -26.70% |
| 1 Year Change | 20.69% |
| 33 Year Change | -70.34% |
| 5 Year Change | -39.39% |
| Change since IPO | -90.91% |
Recent News & Updates
Shareholder Returns
| NNVC | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 2.2% | 4.0% | 2.2% |
| 1Y | 20.7% | 18.3% | 32.6% |
Return vs Industry: NNVC exceeded the US Biotechs industry which returned 18.3% over the past year.
Return vs Market: NNVC underperformed the US Market which returned 32.6% over the past year.
Price Volatility
| NNVC volatility | |
|---|---|
| NNVC Average Weekly Movement | 9.3% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: NNVC has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: NNVC's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 7 | Anil Diwan | www.nanoviricides.com |
NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company’s product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form, which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric treatments. It also offers NV-387 Solution for injection, infusion, and inhalation to treat severe cases that are not hospitalized and carried out by an injection; and injectable solution that delivered directly into the lungs as a fog created using portable battery operated nebulizer devices, which enables action at infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia.
NanoViricides, Inc. Fundamentals Summary
| NNVC fundamental statistics | |
|---|---|
| Market cap | US$19.96m |
| Earnings (TTM) | -US$9.45m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.2x
P/E RatioIs NNVC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NNVC income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$9.45m |
| Earnings | -US$9.45m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.64 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did NNVC perform over the long term?
See historical performance and comparison